Neuronetics (STIM) Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neuronetics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" STIM shares.
View STIM analyst ratings or view top-rated stocks.

2 brokers have issued twelve-month price objectives for Neuronetics' shares. Their STIM share price forecasts range from $7.00 to $12.00. On average, they anticipate the company's share price to reach $9.67 in the next year. This suggests a possible upside of 256.7% from the stock's current price.
View analysts price targets for STIM or view top-rated stocks among Wall Street analysts.

Neuronetics' stock was trading at $6.87 at the start of the year. Since then, STIM shares have decreased by 60.6% and is now trading at $2.71.
View the best growth stocks for 2023 here.

Neuronetics saw a decrease in short interest in May. As of May 15th, there was short interest totaling 304,200 shares, a decrease of 19.8% from the April 30th total of 379,400 shares. Based on an average daily trading volume, of 253,300 shares, the days-to-cover ratio is presently 1.2 days. Approximately 1.2% of the company's shares are sold short.
View Neuronetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 1st 2023.
View our STIM earnings forecast.

Neuronetics, Inc. (NASDAQ:STIM) issued its quarterly earnings results on Tuesday, May, 9th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.01. The company had revenue of $15.54 million for the quarter, compared to analysts' expectations of $15.11 million. Neuronetics had a negative net margin of 55.34% and a negative trailing twelve-month return on equity of 62.22%.

iShares Neuroscience and Healthcare ETF holds 2,895 shares of STIM stock, representing 0.14% of its portfolio.

Neuronetics issued an update on its second quarter 2023 earnings guidance on Tuesday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $17.00 million-$18.00 million, compared to the consensus revenue estimate of $17.30 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Neuronetics investors own include SCYNEXIS (SCYX), Inovio Pharmaceuticals (INO), Novavax (NVAX), Gilead Sciences (GILD), iBio (IBIO), Onconova Therapeutics (ONTX), Pfizer (PFE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT) and Acasti Pharma (ACST).

(STIM) raised $75 million in an initial public offering on Thursday, June 28th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Piper Jaffray and William Blair served as the underwriters for the IPO and Canaccord Genuity, BTIG and JMP Securities were co-managers.

Neuronetics trades on the NASDAQ under the ticker symbol "STIM."

Neuronetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Cannell Capital LLC (10.99%), Silvercrest Asset Management Group LLC (3.41%), Balyasny Asset Management L.P. (3.25%), Acadian Asset Management LLC (1.46%), BlackRock Inc. (1.33%) and Dimensional Fund Advisors LP (1.31%). Insiders that own company stock include Bruce Joseph Shook, Cannell Capital Llc, Gregory Harper, Keith J Sullivan, Paul Liberman, Robert Cascella, Sheryl L Conley, Stephen Furlong and William Andrew Macan.
View institutional ownership trends.

Shares of STIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of STIM stock can currently be purchased for approximately $2.71.

Neuronetics (NASDAQ:STIM) has a market capitalization of $77.10 million and generates $65.21 million in revenue each year. The company earns $-37,160,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis.

The company employs 175 workers across the globe.

Neuronetics' mailing address is 3222 PHOENIXVILLE PIKE, MALVERN PA, 19355. The official website for the company is www.neurostar.com. The company can be reached via phone at (610) 640-4202, via email at ir@neuronetics.com, or via fax at 610-640-4206.